Alyssum Therapeutics is at the forefront of B cell immunotherapy, focusing on the modulation of B cell immune responses to address complex diseases, particularly various solid tumors and autoimmune conditions. B cells play a crucial role in the immune system, and their recruitment and activation have been linked to improved patient outcomes, especially in conjunction with immune checkpoint inhibitors. The company’s lead candidate, AT1965, is a small molecule currently undergoing Phase 1 clinical trials for advanced solid malignancies. This innovative therapy targets CMTR2 in cancer cells, which not only recruits a B cell immune response but has also shown promise in regressing hard-to-treat tumors in preclinical studies.

The therapeutic potential of B cells extends beyond mere recruitment; they can organize immune responses, prime T cells, and directly attack cancer cells through antibody production. AT1965 has demonstrated a significant overall response rate in preclinical models, particularly in challenging breast cancer cases. By inhibiting CMTR2, AT1965 converts cancer cell RNA into viral-like RNA, triggering a robust immune response from B cells. This dual activation of both innate and adaptive immune systems positions B cell modulation as a promising strategy for enhancing antitumor efficacy, potentially surpassing the effectiveness of current immune checkpoint inhibitors.

United States

Alyssum Therapeutics, a biotechnology company which is developing next-generation immunotherapies to modulate B cells

Alyssum Therapeutics

Company Details